+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Biobanking Market Report and Forecast 2024-2032

  • PDF Icon


  • 140 Pages
  • April 2024
  • Region: Global
  • Expert Market Research
  • ID: 5960374
The global biobanking market size was valued at USD 72.1 billion in 2023. It is projected to expand at a CAGR of 6.89% throughout the forecast period from 2024 to 2032, driven by technological innovations and a rising prevalence of injuries across the globe. It is projected to attain a value of USD 131.1 billion by 2032.

Global Biobanking Market Analysis

The global biobanking market has been witnessing significant growth and is poised to continue expanding from 2017 to 2032. This expansion is driven by a combination of factors, each playing a crucial role in shaping the landscape of biobanking. These factors include technological advancements, regulatory landscapes, the growing prevalence of chronic diseases, the rise in biobanking applications, and shifts in funding and investment patterns.

Global Biobanking Market Trends

The global biobanking market has experienced a notable trajectory of growth and transformation between 2017 and 2032, driven by multifaceted trends that reflect advancements in technology, evolving regulatory frameworks, and shifting priorities in medical research and healthcare. These trends not only underscore the expanding role of biobanks in supporting medical research and development but also highlight the challenges and opportunities faced by this sector. Below are the key market trends that have characterized the global biobanking market over this period:
  • Accelerated Technological Integration
The integration of advanced technologies has been a defining trend, enhancing the operational efficiency and capabilities of biobanks. Automation, artificial intelligence (AI), and blockchain technology have revolutionized sample management, data analysis, and security. These technologies have enabled biobanks to manage vast collections of biological samples more effectively, ensuring higher quality standards and facilitating complex research endeavors.
  • Emphasis on Precision Medicine
The rise of precision medicine has significantly impacted the biobanking market, with an increased demand for high-quality biological samples to support targeted research and therapy development. This trend has led to the expansion of specialized biobanks that focus on specific diseases or population groups, facilitating the advancement of personalized healthcare solutions and driving the growth of the biobanking market.
  • Regulatory and Ethical Evolution
The period has seen an evolution in regulatory and ethical frameworks governing biobanking activities, with a focus on enhancing data protection, consent processes, and transparency. These changes reflect a global movement towards harmonizing biobanking practices, ensuring ethical standards, and fostering international collaboration. Navigating these regulatory landscapes has become a critical aspect of biobanking operations, influencing global market dynamics.
  • Expansion of Biobanking Applications
Beyond traditional research uses, biobanking applications have broadened to include fields such as regenerative medicine, biomarker discovery, and the support of clinical trials. This diversification has opened new revenue streams and opportunities for biobanks, contributing to market growth and the enhancement of research and healthcare outcomes.
  • Geographic Diversification
The global biobanking market has witnessed geographic diversification, with significant growth in emerging economies. This trend is driven by increasing investments in healthcare infrastructure, rising prevalence of chronic diseases, and growing recognition of the role of biobanks in medical research. Emerging markets, particularly in the Asia-Pacific region, have become key contributors to the global expansion of biobanking.
  • Sustainable Funding Models
Sustainable funding has emerged as a pivotal trend, with biobanks exploring various models to ensure long-term viability. Government support, private investments, and public-private partnerships have become crucial for the establishment and expansion of biobanking facilities. This trend reflects the growing recognition of biobanks as indispensable resources for health research and the need for sustainable financial strategies.
  • Focus on Patient Engagement and Consent
Patient engagement and informed consent practices have gained prominence, reflecting an increased focus on ethical considerations and patient rights. Biobanks have been adopting more transparent and participatory approaches to consent, enhancing public trust and participation in biobanking activities. This trend underscores the importance of ethical governance and community engagement in the biobanking sector.

Global Biobanking Market Segmentation

Market Breakup by Material

  • Population-based Biobanks
  • Disease-based Biobanks
  • Academic Biobanks
  • Hospital-based Biobanks
  • Commercial Biobanks
In terms of material, the global biobanking market is segmented into various categories, including Population-based Biobanks that collect samples from general communities to support diverse research needs, Disease-based Biobanks which focus on collecting samples related to specific diseases for targeted research, Academic Biobanks associated with educational institutions emphasizing research and education, Hospital-based Biobanks that are linked to hospitals aiming to support clinical research and patient care, and Commercial Biobanks operated by private entities with a focus on profitability. These segments illustrate the diverse infrastructure and objectives within the biobanking field, catering to a wide range of research, clinical, and commercial needs.

Market Breakup by Sample Type

  • Blood Products
  • Human Tissues
  • Nucleic Acids
  • Cell Lines
  • Biological Fluids
  • Others
Within the biobanking market, segmentation is based on the type of sample collected and stored, encompassing a diverse array of biological materials. These segments include blood products, which are crucial for a wide range of medical research and therapeutic applications; human tissues, offering invaluable insights into disease mechanisms and treatment responses; nucleic acids, essential for genetic and genomic studies; cell lines, used extensively in research for understanding disease progression and drug development; biological fluids, which provide critical biomarkers for various conditions; and Other sample types that cater to specialized research needs. This segmentation underscores the comprehensive nature of biobanking services, addressing the multifaceted requirements of medical and scientific research.

Market Breakup by Application

  • Drug Discovery and Development
  • Personalized Medicine
  • Regenerative Medicine
  • Clinical Research
  • Forensics
  • Others
In the context of the biobanking market, segmentation is delineated by diverse applications, each serving a unique role in biomedical research and healthcare. These segments include Drug Discovery and Development, where biobanks provide essential biological samples for identifying new therapeutic targets and testing pharmaceutical compounds. Personalized Medicine utilizes biobanked samples to tailor treatments to individual genetic profiles, enhancing efficacy and reducing side effects. Regenerative Medicine relies on stored biological materials to advance research in tissue engineering and cellular therapies.

Clinical Research benefits from biobanked samples to conduct studies on disease mechanisms, treatment outcomes, and epidemiological insights. Forensics uses biobanked DNA and other samples for identification purposes and in solving crimes. The "Others" category encompasses additional applications such as biomarker discovery, nutritional research, and environmental health studies. This segmentation underscores the multifaceted contributions of biobanking to various fields, reflecting its integral role in advancing medical science and improving patient care.

Market Breakup by Ownership

  • Public Biobanks
  • Private Biobanks
  • Hybrid Biobanks
In the biobanking market, segmentation by ownership plays a crucial role in understanding the dynamics and operational frameworks that underpin this sector. The market is segmented into public biobanks, private biobanks, and hybrid biobanks. Public biobanks are typically funded and operated by government or academic institutions and focus on supporting research that benefits the public health sector. They are essential for advancing medical research, housing a wide array of samples for various diseases and conditions. Private biobanks, on the other hand, are owned and managed by private entities and often focus on specific research areas or commercial applications, including pharmaceutical and biotechnological research. Hybrid biobanks represent a collaborative model, combining elements of both public and private ownership. This segment aims to leverage the strengths of both sectors, facilitating broader access to samples and data while promoting innovation through private investment. These segments collectively underscore the diverse ecosystem of the biobanking market, reflecting different funding sources, operational goals, and user communities.

Market Breakup by Source

  • Human Biobanks
  • Animal Biobanks
  • Plant Biobanks
The biobanking market is intricately segmented by source, encompassing human biobanks, animal biobanks, and plant biobanks, each catering to distinct research needs and applications. Human Biobanks, pivotal in medical research, store biological samples from human donors, supporting advancements in personalized medicine and disease understanding. Animal Biobanks play a crucial role in veterinary and pharmaceutical research, facilitating the study of disease models and the development of therapeutic solutions. Plant Biobanks, meanwhile, are essential for agricultural research and biodiversity conservation, preserving genetic material of various plant species for future studies and crop improvement efforts. This segmentation underscores the diverse applications of biobanking, highlighting its integral role in advancing scientific research across different domains.

Market Breakup by End User

  • Biopharmaceutical Companies
  • Research and Academic Institutes
  • Hospitals
  • Contract Research Organizations (CROs)
  • Others
The biobanking market serves a diverse range of segments, including Biopharmaceutical Companies that leverage biobanks for drug discovery and development, Research and Academic Institutes utilizing biological samples for scientific investigation and education, Hospitals employing biobanking for diagnostic purposes and personalized medicine, Contract Research Organizations (CROs) that rely on biobanks for clinical trials and research projects, and Others encompassing private biobanks and governmental organizations dedicated to public health research. Each segment underscores the integral role of biobanks in advancing medical research, therapeutic development, and clinical diagnostics, reflecting the multifaceted applications and value of biobanking across the healthcare and research spectrum.

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
The biobanking market is segmented geographically into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa, each exhibiting unique growth dynamics and contributing to the global market landscape. North America leads with a robust infrastructure for research and development, followed by Europe with its stringent regulatory frameworks ensuring high-quality biobanking practices. The Asia Pacific region is rapidly emerging as a significant player due to increasing investments in healthcare and research. Latin America and the Middle East and Africa are witnessing gradual growth, driven by the expanding recognition of biobanking's role in medical research and the improvement of healthcare outcomes. This geographic segmentation underscores the global reach and diversity of the biobanking market, reflecting varied regional priorities, regulatory environments, and investment levels.

Global Biobanking Market Competitive Landscape

The global biobanking market is highly fragmented and competitive, with the presence of several players, such as Thermo Fisher Scientific Inc., Brooks Automation, Inc., Qiagen N.V., Tecan Group Ltd., Hamilton Company, Chart Industries, Inc., PHC Holdings Corporation, Becton, Dickinson and Company (BD), Panasonic Healthcare Holdings Co., Ltd., STEMCELL Technologies Inc., Lifenet Health, Promega Corporation, Greiner Bio-One International GmbH, Lonza Group AG. These players are engaged in various strategies, such as product launches and enhancements, mergers and acquisitions, partnerships and collaborations, and expansions and investments, to gain a competitive edge and increase their market share.

Key Questions Answered in This Report

  • How did the biobanking market perform globally from 2017 to 2023, and what are the forecasts for its growth until 2032?
  • What technological innovations have had a major impact on the biobanking market?
  • How do key drivers, restraints, and opportunities affect the biobanking market?
  • Which regions are the key markets in the global biobanking scenario?
  • Which countries are emerging as the most promising markets for biobanking?
  • How is the biobanking market segmented by the material of biobank?
  • Which source of biobank is the most valuable for veterinary and pharmaceutical research?
  • How is the biobanking market divided by the type of samples application and ownership?
  • How is the competitive landscape shaped in the biobanking market?
  • Who are the leading companies and organizations in the biobanking market?

Key Benefits for Stakeholders

  • The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the biobanking market from 2017-2032.
  • The research report provides the latest information on the market drivers, challenges, and opportunities in the global biobanking market.
  • The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
  • Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the biobanking industry and its attractiveness.
  • The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

This product will be delivered within 5-7 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Biobanking Market Overview
3.1 Global Biobanking Market Historical Value (2017-2023)
3.2 Global Biobanking Market Forecast Value (2024-2032)
4 Global Biobanking Market Landscape*
4.1 Global Biobanking: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Biobanking: Product Landscape
4.2.1 Analysis by Material
4.2.2 Analysis by Sample Type
5 Global Biobanking Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Biobanking Market Segmentation (2017-2032)
6.1 Global Biobanking Market (2017-2032) by Material
6.1.1 Market Overview
6.1.2 Population-based Biobanks
6.1.3 Disease-based Biobanks
6.1.4 Academic Biobanks
6.1.5 Hospital-based Biobanks
6.1.6 Commercial Biobanks
6.2 Global Biobanking Market (2017-2032) by Sample Type
6.2.1 Market Overview
6.2.2 Blood Products
6.2.3 Human Tissues
6.2.4 Nucleic Acids
6.2.5 Cell Lines
6.2.6 Biological Fluids
6.2.7 Others
6.3 Global Biobanking Market (2017-2032) by Application
6.3.1 Market Overview
6.3.2 Drug Discovery and Development
6.3.3 Personalized Medicine
6.3.4 Regenerative Medicine
6.3.5 Clinical Research
6.3.6 Forensics
6.3.7 Others
6.4 Global Biobanking Market (2017-2032) by Ownership
6.4.1 Market Overview
6.4.2 Public Biobanks
6.4.3 Private Biobanks
6.4.4 Hybrid Biobanks
6.5 Global Biobanking Market (2017-2032) by Source
6.5.1 Market Overview
6.5.2 Human Biobanks
6.5.3 Animal Biobanks
6.5.4 Plant Biobanks
6.6 Global Biobanking Market (2017-2032) by End User
6.6.1 Market Overview
6.6.2 Biopharmaceutical Companies
6.6.3 Research and Academic Institutes
6.6.4 Hospitals
6.6.5 Contract Research Organizations (CROs)
6.6.6 Others
6.7 Global Biobanking Market (2017-2032) by Region
6.7.1 Market Overview
6.7.2 North America
6.7.3 Europe
6.7.4 Asia Pacific
6.7.5 Latin America
6.7.6 Middle East and Africa
7 North America Biobanking Market (2017-2032)
7.1 North America Biobanking Market (2017-2032) by Material
7.1.1 Market Overview
7.1.2 Population-based Biobanks
7.1.3 Disease-based Biobanks
7.1.4 Academic Biobanks
7.1.5 Hospital-based Biobanks
7.1.6 Commercial Biobanks
7.2 North America Biobanking Market (2017-2032) by Sample Type
7.2.1 Market Overview
7.2.2 Blood Products
7.2.3 Human Tissues
7.2.4 Nucleic Acids
7.2.5 Cell Lines
7.2.6 Biological Fluids
7.2.7 Others
7.3 North America Biobanking Market (2017-2032) by Country
7.3.1 United States of America
7.3.2 Canada
8 Europe Biobanking Market (2017-2032)
8.1 Europe Biobanking Market (2017-2032) by Material
8.1.1 Market Overview
8.1.2 Population-based Biobanks
8.1.3 Disease-based Biobanks
8.1.4 Academic Biobanks
8.1.5 Hospital-based Biobanks
8.1.6 Commercial Biobanks
8.2 Europe Biobanking Market (2017-2032) by Sample Type
8.2.1 Market Overview
8.2.2 Blood Products
8.2.3 Human Tissues
8.2.4 Nucleic Acids
8.2.5 Cell Lines
8.2.6 Biological Fluids
8.2.7 Others
8.3 Europe Biobanking Market (2017-2032) by Country
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Others
9 Asia Pacific Biobanking Market (2017-2032)
9.1 Asia Pacific Biobanking Market (2017-2032) by Material
9.1.1 Market Overview
9.1.2 Population-based Biobanks
9.1.3 Disease-based Biobanks
9.1.4 Academic Biobanks
9.1.5 Hospital-based Biobanks
9.1.6 Commercial Biobanks
9.2 Asia Pacific Biobanking Market (2017-2032) by Sample Type
9.2.1 Market Overview
9.2.2 Blood Products
9.2.3 Human Tissues
9.2.4 Nucleic Acids
9.2.5 Cell Lines
9.2.6 Biological Fluids
9.2.7 Others
9.3 Asia Pacific Biobanking Market (2017-2032) by Country
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 ASEAN
9.3.5 Australia
9.3.6 Others
10 Latin America Biobanking Market (2017-2032)
10.1 Latin America Biobanking Market (2017-2032) by Material
10.1.1 Market Overview
10.1.2 Population-based Biobanks
10.1.3 Disease-based Biobanks
10.1.4 Academic Biobanks
10.1.5 Hospital-based Biobanks
10.1.6 Commercial Biobanks
10.2 Latin America Biobanking Market (2017-2032) by Sample Type
10.2.1 Market Overview
10.2.2 Blood Products
10.2.3 Human Tissues
10.2.4 Nucleic Acids
10.2.5 Cell Lines
10.2.6 Biological Fluids
10.2.7 Others
10.3 Latin America Biobanking Market (2017-2032) by Country
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Mexico
10.3.4 Others
11 Middle East and Africa Biobanking Market (2017-2032)
11.1 Middle East and Africa Biobanking Market (2017-2032) by Material
11.1.1 Market Overview
11.1.2 Population-based Biobanks
11.1.3 Disease-based Biobanks
11.1.4 Academic Biobanks
11.1.5 Hospital-based Biobanks
11.1.6 Commercial Biobanks
11.2 Middle East and Africa Biobanking Market (2017-2032) by Sample Type
11.2.1 Market Overview
11.2.2 Blood Products
11.2.3 Human Tissues
11.2.4 Nucleic Acids
11.2.5 Cell Lines
11.2.6 Biological Fluids
11.2.7 Others
11.3 Middle East and Africa Biobanking Market (2017-2032) by Country
11.3.1 Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Nigeria
11.3.4 South Africa
11.3.5 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication Year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by Year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by Departments
14.7 Analysis by Recipient Organization
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Thermo Fisher Scientific Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Brooks Automation, Inc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Qiagen N.V.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Tecan Group Ltd.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Hamilton Company
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Chart Industries, Inc.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 PHC Holdings Corporation
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Becton, Dickinson and Company (BD)
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Merck KGaA
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Panasonic Healthcare Holdings Co., Ltd.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 STEMCELL Technologies Inc.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Lifenet Health
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Promega Corporation
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Greiner Bio-One International GmbH
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 Lonza Group AG
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
List not exhaustive
18 Global Biobanking Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The research team strives to make this section as comprehensive as possible.

Companies Mentioned

  • Thermo Fisher Scientific Inc.
  • Brooks Automation Inc.
  • Qiagen N.V. Tecan Group Ltd.
  • Hamilton Company
  • Chart Industries Inc.
  • PHC Holdings Corporation
  • Becton, Dickinson and Company (BD) Merck KGaA
  • Panasonic Healthcare Holdings Co. Ltd.
  • STEMCELL Technologies Inc.
  • Lifenet Health
  • Promega Corporation
  • Greiner Bio-One International GmbH
  • Lonza Group AG